Skip to main content
. Author manuscript; available in PMC: 2012 Aug 16.
Published in final edited form as: Oncogene. 2011 Jul 11;31(7):828–841. doi: 10.1038/onc.2011.277

FIGURE 1. Differential regulation and requirement of p53 in melanoma cells and normal melanocytes.

FIGURE 1

A, Protein immunoblots depicting p53 leves in basal conditions and upon treatment with doxorubicin (DOX, 0.5 μg/mL). B, Quantification of data in A as determined by densitometry. Shown are arbitrary units (AU) normalized to actin. C, Proliferative capacity of p53 shRNA-expressing melanoma cells versus their non-infected or control shRNA counterparts. D, Global assessment of DNA damage comet assay. Doxorubicin is shown as a control for DNA damage (far right panel). E, Microphotographs of indicated melanoma lines following ectopic overexpression of p53 (day 7). F, Protein immunoblots to visualize total p53, activated p53 (phosphorylated on Ser 15) and the p53 targets MDM2 and p21.